Posts by: Alice Melão

News

Adding investigational therapy chidamide to Aromasin (exemestane) significantly delayed disease progression or death in patients with advanced breast cancer, results from a Phase 3 trial show. This means that the pivotal trial (NCT02482753) ... Read more

June 18, 2018

Zejula-Keytruda Shows Promising Response Rates for Triple-negative Breast Cancer in Phase 1/2 Trial

News

A combination of Keytruda (pembrolizumab) and Zejula (niraparib) has shown promising and durable response rates in triple-negative breast cancer patients, regardless of their BRCA mutational status, Phase 1/2 trial data show. The ... Read more

May 11, 2018

OncoSec, Merck Partner to Test Immunotherapy Combo in Phase 2 Trial for Triple-negative Breast Cancer

News

OncoSec Medical and Merck have joined efforts to conduct a Phase 2 trial evaluating the safety and effectiveness of ImmunoPulse IL-12 in combination with Keytruda (pembrolizumab) for the treatment ... Read more

May 2, 2018

ADC Therapeutics Halts ADCT-502 Development, Phase 1 Trial for HER2-positive Cancers

News

ADC Therapeutics has halted the development of ADCT-502, an investigational treatment candidate for HER2-positive solid cancers, and terminated its Phase 1 trial after it failed to show sufficient patient ... Read more

April 9, 2018

Breast Cancer Patients with Very Small Tumors May Skip Lymph Node Biopsies, Study Suggests

News

Patients with very small, invasive breast tumors — called microinvasive breast carcinomas — may not benefit from lymph node biopsies, researchers from Allina Health suggest. The study, “Clinicopathologic analysis of a ... Read more

February 19, 2018February 19, 2018

Breast Cancer Study Finds Exercise During Chemo Can Become Long-term Habit

News

Breast and colon cancer patients who exercise during their chemotherapy program are more likely to remain physically active long term than those receiving usual care, a trial shows. Four ... Read more

February 9, 2018February 9, 2018

7 in 10 Metastatic Breast Cancer Patients Benefit from LiPlaCis, Early Trial Data Shows

News

A targeted liposomal formulation of the chemotherapy treatment cisplatin, called LiPlaCis, induced clinical benefit in 70 percent of breast cancer patients included in a Phase 1/2 trial. The clinical response, ... Read more

January 24, 2018

Estrogen-like Compounds in Diet May Reduce Effectiveness of Breast Cancer Treatment

News

Breast cancer patients taking Ibrance (palbociclib) plus Femara (letrozole), an approved combination for the disease, should avoid diets rich in estrogen-like compounds, researchers say. Their research shows that these compounds, called ... Read more

January 22, 2018

MammaTyper Test Able to Identify Women at Low Risk of Breast Cancer Spreading, Studies Show

News

BioNTech Diagnostics’ MammaTyper test lets doctors determine the type of breast cancer a woman has and identify patients at low risk of having their cancer spread. The company discussed the diagnostic ... Read more

December 15, 2017December 15, 2017

Myriad’s riskScore Predicts Lifetime Breast Cancer Risk in Women Without Hereditary Gene Mutations

News

Myriad Genetics has developed a new test, called riskScore, that accurately predicts the five-year and lifetime risk of breast cancer in women who tested negative for hereditary mutations in breast ... Read more

Posts by: Alice Melão

Alice Melão

Phase 3 Trial Testing Aromasin-Chidamide Combo for Advanced Breast Cancer Meets Primary Goal

Zejula-Keytruda Shows Promising Response Rates for Triple-negative Breast Cancer in Phase 1/2 Trial

OncoSec, Merck Partner to Test Immunotherapy Combo in Phase 2 Trial for Triple-negative Breast Cancer

ADC Therapeutics Halts ADCT-502 Development, Phase 1 Trial for HER2-positive Cancers

Breast Cancer Patients with Very Small Tumors May Skip Lymph Node Biopsies, Study Suggests

Breast Cancer Study Finds Exercise During Chemo Can Become Long-term Habit

7 in 10 Metastatic Breast Cancer Patients Benefit from LiPlaCis, Early Trial Data Shows

Estrogen-like Compounds in Diet May Reduce Effectiveness of Breast Cancer Treatment

MammaTyper Test Able to Identify Women at Low Risk of Breast Cancer Spreading, Studies Show

Myriad’s riskScore Predicts Lifetime Breast Cancer Risk in Women Without Hereditary Gene Mutations

Pin It on Pinterest